News Insight Wellness Events Consumer Investor / VC

WHIS 2025: Driving the future of women’s health

By Published On: August 20, 2025
WHIS 2025: Driving the future of women’s health

As we all know too well, for decades, women’s health has been an overlooked corner of medicine.

Research has often excluded women, leading to gaps in understanding, and funding has lagged behind other areas of healthcare.

Yet in recent years, a quiet revolution has been taking shape.

Startups, clinicians, and investors have begun to focus on conditions that affect half the population, from endometriosis to menopause, fertility to cardiovascular disease.

The result is a wave of innovation but one that faces challenges in scaling and adoption without stronger collaboration across the healthcare system.

That is where WHIS (Women’s Health Innovation Summit) comes in.

Now in its seventh year, the gathering has become a rare forum that spans the full breadth of women’s health.

It brings together payers, providers, big pharma, consumer health companies, digital health innovators, investors, and early-stage startups under one roof.

The idea is simple: progress in women’s health requires everyone in the chain—from research to delivery of care—to share knowledge and align on priorities.

This year, the summit has expanded its focus on payers and providers. Their presence is crucial.

New ideas and technologies only have impact if they can find their way into the complex realities of healthcare delivery and reimbursement.

By including those voices more prominently, the event aims to make sure that conversations about innovation are grounded in practical pathways to adoption.

It is an acknowledgment that good science alone is not enough; systems and incentives must also evolve to meet the needs of women.

The programme reflects the diversity of perspectives shaping the field.

Leaders from Kaiser Permanente, IVI RMA Global, McKinsey & Company, Maven Clinic, and Kindbody are set to share insights, covering everything from reproductive medicine to digital platforms and strategy.

They will be joined by representatives from Mass General Brigham, Beckman Coulter, Eli Lilly, Kimberly-Clark, and CVS Health, each bringing experience from different corners of healthcare and life sciences.

Alongside them, early-stage companies will present technologies that could redefine diagnostics, therapeutics, and medical devices for women’s health.

What makes WHIS particularly significant is the way it spotlights both the structural challenges and the opportunities for transformation.

Women’s health has long suffered from fragmented approaches, where reproductive issues were siloed from broader conversations about chronic disease, mental health, or ageing.

The summit underscores the reality that women’s health is not a niche, but a spectrum that intersects with every stage of life and every part of the healthcare system.

For attendees, the event is less about promotion and more about building the relationships and strategies needed to change how women’s health is treated, funded, and prioritised.

It is a space where clinicians can meet entrepreneurs, where established players can learn from nimble startups, and where investors can better understand the long-term value of supporting women’s health innovation.

The conversations that begin here have the potential to ripple far beyond the conference walls.

As the summit enters its seventh year, it stands as both a marker of progress and a reminder of how much work remains.

Women’s health has momentum but ensuring that momentum translates into impact requires sustained commitment across science, business, and policy.

WHIS offers a chance to take part in that effort.

Registration is now open, with super early bird pricing available until Friday, 22 August. You can register here

Shrinking the gender health gap through innovation in clinical trial AI
Breaking barriers: How WUKA’s Tackle Anything campaign ss changing grassroot sports